Cardio Diagnostics Deploys Epigenetic Biomarkers to Expose Hidden Heart Disease Risks
CDIO•Cardio Diagnostics Holdings has positioned epigenetics at the center of its cardiovascular diagnostic platform, analyzing gene expression markers to assess lifestyle and environmental impacts on heart disease risk. The platform identifies epigenetic biomarkers that reveal hidden cardiovascular risks beyond DNA sequence, offering personalized insights for tailored prevention strategies.
1. Epigenetic Diagnostic Platform
Cardio Diagnostics has integrated epigenetics-based testing into its cardiovascular diagnostic platform, focusing on gene expression modifications rather than DNA sequence alone to assess heart disease risk.
2. Mechanism of Action
The test analyzes specific epigenetic biomarkers that reflect how lifestyle, behavior and environment turn genes on or off, revealing hidden cardiovascular risks traditional genetic tests may miss.
3. Personalized Risk Insights
By quantifying individual epigenetic changes, the platform provides tailored insights into modifiable factors contributing to heart disease, potentially guiding targeted prevention and intervention strategies.
